Coexisting Myeloperoxidase (MPO)-ANCA Vasculitis and Alport Syndrome (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0130; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She was initially treated for the primary GPA diagnosis with methotrexate and later transitioned to rituximab due to liver enzyme elevation. This distinction is crucial, as AS does not account for her systemic manifestations, thereby demonstrating the coexistence of two distinct pathologies. The case further highlights the role of genetic testing in uncovering underlying genetic kidney disease."
ANCA Vasculitis • Chronic Kidney Disease • Cough • Fibrosis • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Immunology • Infectious Disease • Lupus Nephritis • Nephrology • Otorhinolaryngology • Pulmonary Disease • Renal Calculi • Renal Disease • Respiratory Diseases • Urology • Vasculitis • MPO
|
|
Amir Tahavvori; Niloufar Ebrahimi; Yan Chen Wongworawat; Amir Abdi Pour
|